Non-Animal Testing Methods now sit closer to day-to-day chemical compliance because EPA took several public actions in 2026 to expand how New Approach Methodologies, or NAMs, can be used in chemical review. On June 2, 2026, EPA updated its TSCA NAMs list for the first time in five years, adding 13 methods from external authoritative bodies and introducing a streamlined nomination process for researchers, companies, and NGOs, according to the June 2, 2026 EPA announcement.

For manufacturers, importers, formulators, and compliance teams, the practical question is not whether animal testing disappears from every regulatory file. The narrower question is whether a specific method is accepted for a specific endpoint, under a specific statute, for a specific decision. That distinction should shape how companies document hazard information, supplier data, test selection, and uncertainty in TSCA and adjacent compliance records.

What EPA Changed For Non-Animal Testing Methods

The June 2026 TSCA List Update

EPA’s June 2, 2026 update added NAMs that included reconstructed human cell methods for assessing eye hazards, a 3D human cell-based tissue model for phototoxicity, and combinations of OECD-validated in vitro and in chemico tests for dermal sensitization hazard, potency, and quantitative point-of-departure. These examples matter because they are not a single substitute for all toxicology questions. They are method categories tied to particular biological effects and regulatory uses.

The streamlined nomination process also changed the administrative pathway. Researchers, companies, and NGOs could submit NAMs for consideration in TSCA chemical risk evaluations. That makes method tracking a compliance activity rather than a research-only topic. A company that relies on a NAM should be prepared to identify the method, its source, its validation or acceptance status, its endpoint, and the limits of the decision it can support.

Where Non-Animal Testing Methods Fit

EPA’s January 2026 memo formally recommitted the agency to eliminating mammalian testing by 2035. The same memo stated that EPA used high-quality non-animal methods in 2025 TSCA risk evaluations for dibutyl phthalate and di(2-ethylhexyl) phthalate to evaluate cancer risk, with an estimated 1,600 mice and rats spared from lethal testing. That example shows agency use in a defined risk-evaluation setting, but it should not be read as approval for every substance, exposure pathway, or endpoint.

On August 27, 2026, EPA also announced two scientific advancements: use of 3D human airway tissue to modernize surfactant inhalation hazard assessment, and adoption of the GHS mixtures equation to estimate oral toxicity for certain pesticide formulations, based on analysis of nearly 700 pesticide formulations. The pesticide example is especially relevant for formulators because mixture rules can affect whether a new animal study is needed, but only where the method and product type fall within the accepted scope.

Why The Shift Matters For Compliance Files

Evidence Must Match The Regulatory Question

Non-Animal Testing Methods do not remove the need for controlled evidence. They change the type of evidence that may be acceptable. A compliance file should show why a selected method is suitable for the hazard endpoint, route of exposure, chemical class, mixture type, or risk-evaluation question at issue. A NAM that is informative for eye irritation is not automatically informative for chronic systemic toxicity. A method useful for screening may not be enough for a quantitative risk value unless the regulatory context allows that use.

EPA’s NAMs Work Plan, originally released in June 2020 and updated in December 2021, set five objectives: evaluating regulatory flexibility, developing baselines and metrics, establishing scientific confidence, developing NAMs to fill gaps, and engaging stakeholders. Those objectives are a useful checklist for industry files because they separate legal acceptance from scientific confidence. Both are needed before a method can support a defensible compliance decision.

For a closer discussion of endpoint fit and validation limits, the site’s related analysis of risk review methods addresses similar documentation questions.

Supplier Records Need Method Context

A supplier statement that a chemical was assessed using a NAM may be too general for audit or agency review. Compliance personnel should request the method name, protocol or guideline reference where available, test system, endpoint, acceptance status, decision criteria, and any stated limitations. Where the method is part of a defined combination, such as in vitro and in chemico tests for dermal sensitization, the file should preserve the logic of the combination rather than treating each result as a stand-alone certificate.

For companies managing procurement records across linked industries, you might find it insightful to review Mengo Industrial as part of the same network of industrial information resources. However, chemical-specific regulatory judgments should remain tied to source documents and qualified review.

Compliance Implications Of Non-Animal Testing Methods

TSCA Reviews And Method Acceptance

A compliance file built around Non-Animal Testing Methods should make clear whether the method is being used for internal screening, supplier qualification, hazard classification, risk evaluation support, or response to an agency order. Those are different uses. A screening result can help prioritize work, but it may not satisfy a statutory data need unless EPA has accepted that type of evidence for that purpose.

The October 16, 2025 EPA report described many U.S. environmental statutes and regulations as broad enough to allow data from NAMs, including in vitro, in chemico, and in silico approaches, for hazard and risk assessments rather than requiring vertebrate animal testing in all cases. That finding is significant, but it is not a blanket exemption. Broad legal flexibility still leaves method-by-method questions about scientific confidence, endpoint coverage, exposure relevance, and uncertainty.

Orders, Petitions, And Conditional Pathways

The Fluorotelomer Consortium v. EPA petition materials cited in the research provide a useful compliance signal. EPA included an in vitro dermal absorption test as part of an order to evaluate dermal exposure, with the possibility of foregoing further in vivo dermal testing if the non-animal test supplied adequate safety data. That structure is conditional. It does not say that in vivo testing can never be required; it says a non-vertebrate method may be used first where EPA considers it appropriate.

That conditional model is likely to be familiar to compliance teams. Many chemical files already rely on decision trees, waivers, read-across, weight-of-evidence narratives, and endpoint-specific data packages. NAMs can fit into that structure, but the file should preserve the agency logic or scientific rationale that supports the chosen path.

Implementation Barriers For Chemical Suppliers

Validation And Endpoint Coverage

The main implementation barrier is not only whether a method exists. It is whether the method has enough acceptance and relevance for the compliance decision. Some NAMs are OECD-validated or drawn from external authoritative bodies. Others may be earlier in regulatory use or suitable only for a narrower category of substances. A cautious file should avoid broad statements such as “animal testing is not required” unless the company can point to the applicable rule, guidance, order, or accepted method scope.

Endpoint gaps also remain. Eye hazard, phototoxicity, dermal sensitization, dermal absorption, airway irritation, and mixture oral toxicity are not identical regulatory questions. Chemical suppliers may need to maintain conventional toxicology records, exposure information, safety data sheets, composition evidence, and agency correspondence alongside NAM-based data.

Document Controls For Audit Readiness

Practical controls should be simple enough for procurement, regulatory affairs, and EHS teams to use consistently. Useful records include:

• The exact NAM, protocol, or guideline used, including version or source where available.
• The endpoint, exposure route, and substance or mixture scope addressed by the method.
• The regulatory use claimed, such as screening, classification support, TSCA risk evaluation support, or response to an EPA order.
• The rationale for relying on the method, including validation status, agency acceptance, and known limits.
• Change controls for supplier formulations, impurity profiles, test updates, and new agency guidance.

Between fiscal years 2018 and 2021, EPA’s Office of Research and Development reported a two-thirds decline in the number of vertebrate animals used in studies it conducts. That trend supports the direction of agency research practice. It does not remove the need for companies to maintain clear, reviewable files showing why a non-animal method was appropriate for their own chemical and regulatory context.

Non-Animal Testing Methods In Chemical Compliance

A Practical Compliance Position

The safest compliance position is evidence-based and narrow. EPA’s 2026 actions show stronger agency movement toward NAMs, including TSCA list updates, a nomination pathway, airway tissue models, mixture equations, and a 2035 mammalian-testing goal. Those actions are meaningful for chemical compliance because they create more opportunities to avoid unnecessary vertebrate testing where accepted methods can answer the relevant question.

They also require more disciplined documentation. Chemical companies should treat each NAM as a defined piece of regulatory evidence, not as a general replacement for toxicology review. The file should show the method, the endpoint, the decision being supported, the acceptance basis, and the uncertainty that remains. That approach aligns with EPA’s stated movement while avoiding unsupported claims that could weaken an audit, submission, or agency response.